It was a time for Mylan NV and the US FDA to celebrate, as the agency gave its first ever blessing to a generic of the hard-to-copy Advair Diskus (fluticasone propionate and salmeterol inhalation powder). Advair Diskus, along with EpiPen (epinephrine injection), have long epitomized the difficulties of copying complex products.
At least two companies were hit with complete response letters (CRLs):Alkermes PLC and Sunovion Pharmaceuticals Inc. for their...








